(NASDAQ:AUTL), Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel's adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T […]

(AUST:DTZ.AX),(Other OTC:DTZZF),(Other OTC:DTZNY), SYDNEY, Dec. 08, 2025 (GLOBE NEWSWIRE) — Dotz Nano Limited (ASX: DTZ, OTC: DTZZF/DTZNY, “Dotz” or “Company”), a leading developer of innovative climate and industrial nanotechnologies, today announced that Sharon Malka, Chief Executive Officer, will present at the Small Cap Growth Virtual Investor Conference on Tuesday, December 9, 2025 at 11:30 am

(TSX-V:TELO),(Other OTC:TDSGF), TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF), based in Toronto, a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics platform, today announced that Guido Baechler, Executive Chairman, will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 GlobeNewswire December 08, 2025 Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome

Dotz Nano to Present at the Small Cap Growth Virtual Investor Conference December 9th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com GlobeNewswire December 08, 2025 SYDNEY, Dec. 08, 2025 (GLOBE NEWSWIRE) — Dotz Nano Limited (ASX: DTZ, OTC: DTZZF/DTZNY, “Dotz” or “Company”), a leading developer

Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com GlobeNewswire December 08, 2025 TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF), based in Toronto, a leader

Enterprises gain real-time visibility and control over post-signature obligations, helping reduce risk, enforce compliance, and accelerate business outcomes, turning contract data into operational intelligence Agiloft, the global leader in data-first contract lifecycle management (CLM), today announced the release of its AI-driven Obligation Managementsolution, a suite of breakthrough capabilities that empowers enterprises to transform contracts into

Collaboration with Science Tokyo spinout underscores GlycoNex's integrated antibody development and manufacturing capabilities in support of first-in-class immunotherapies GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a CDMO service agreement with the Institute of Science

Lead product GelrinC®, a hydrogel synchronized erosion and resorbable implant, the only restorative product for knee cartilage repair, is a breakthrough effective and economical procedure to address a large unmet need GelrinC is approved for knee cartilage repair in the European Union and is currently at midpoint in a pivotal FDA trial for the same

The TurfMutt Foundation, which advocates for the care and use of backyards, public parks, school yards and other green spaces, predicts 2026 will be a year of purpose, precision and pet-friendly landscapes. The era of the purely aesthetic lawn is over; the future is about the high-performance, consciously-designed landscape. https://mma.prnewswire.com/media/2840128/Mulligan_and_TurfMutt_cooling_off_in_the_shade__1.jpg “Your yard is no longer